From eye drops for glaucoma to chewing gum for irritable bowel syndrome, cannabis derivatives are making their way into FDA-approved trials, according to a report from MedCityNews. Chief among the molecules of interest is cannabidiol (CBD), which does not deliver a hallucinogenic high. The chemical formula for CBD is C21H30O2.
Companies are applying cannabis-containing compounds to psychiatric illnesses, neurological disorders, and skin and digestive diseases.
The article lists five biopharma companies that are hoping to break into the cannabis therapeutics market.
Source: MedCityNews; February 6, 2017.